{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["29"],"submitter":["Madison BB"],"pubmed_abstract":["The use of T cells from healthy donors for allogeneic chimeric antigen receptor T (CAR-T) cell cancer therapy is attractive because healthy donor T cells can produce versatile off-the-shelf CAR-T treatments. To maximize safety and durability of allogeneic products, the endogenous T cell receptor and major histocompatibility complex class I molecules are often removed via knockout of T cell receptor beta constant (<i>TRBC</i>) (or T cell receptor alpha constant [<i>TRAC</i>]) and <i>B2M</i>, respectively. However, gene editing tools (e.g., CRISPR-Cas9) can display poor fidelity, which may result in dangerous off-target mutations. Additionally, many gene editing technologies require T cell activation, resulting in a low percentage of desirable stem cell memory T cells (T<sub>SCM</sub>). We c"],"journal":["Molecular therapy. Nucleic acids"],"pagination":["979-995"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9481872"],"repository":["biostudies-literature"],"pubmed_title":["Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of T<sub>SCM</sub>-enriched allogeneic CAR-T cells."],"pmcid":["PMC9481872"],"pubmed_authors":["Marquez K","Ostertag EM","Patil D","Tong M","Shedlock DJ","Richter M","Xi H","Li X","Coronella J","Weiss L","Madison BB","Tan Y","Cranert S","Wang X","Martin R"],"additional_accession":[]},"is_claimable":false,"name":"Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of T<sub>SCM</sub>-enriched allogeneic CAR-T cells.","description":"The use of T cells from healthy donors for allogeneic chimeric antigen receptor T (CAR-T) cell cancer therapy is attractive because healthy donor T cells can produce versatile off-the-shelf CAR-T treatments. To maximize safety and durability of allogeneic products, the endogenous T cell receptor and major histocompatibility complex class I molecules are often removed via knockout of T cell receptor beta constant (<i>TRBC</i>) (or T cell receptor alpha constant [<i>TRAC</i>]) and <i>B2M</i>, respectively. However, gene editing tools (e.g., CRISPR-Cas9) can display poor fidelity, which may result in dangerous off-target mutations. Additionally, many gene editing technologies require T cell activation, resulting in a low percentage of desirable stem cell memory T cells (T<sub>SCM</sub>). We c","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-22T03:30:22.507Z","creation":"2025-04-05T20:45:39.18Z"},"accession":"S-EPMC9481872","cross_references":{"pubmed":["36189080"],"doi":["10.1016/j.omtn.2022.06.003"]}}